Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN21515674
ISRCTN21515674
Completed
未知

Effectiveness and safety of nebulized budesonide in controlling acute wheezing in under three-year-olds who are unresponsive to fenoterol

The University of Medicine of Botucatu (UNESP) (Brazil)0 sites75 target enrollmentJanuary 14, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsWheezing in childrenRespiratory

Overview

Phase
未知
Intervention
Not specified
Conditions
Wheezing in children
Sponsor
The University of Medicine of Botucatu (UNESP) (Brazil)
Enrollment
75
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 14, 2008
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
The University of Medicine of Botucatu (UNESP) (Brazil)

Eligibility Criteria

Inclusion Criteria

  • •1\. Children from 1 month to 3 years old
  • •2\. Moderate to very severe acute wheezing, defined by a modified Wood clinical score over 3 after three doses of fenoterol at 20 minute intervals

Exclusion Criteria

  • •1\. Previous use of systemic corticosteroid
  • •2\. Inhalation of corticosteroid or topical corticosteroid in the past 10 days
  • •3\. Cardiopathy
  • •4\. Nephropathy
  • •5\. Neuropathy
  • •6\. Inadequate nutritional level

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Evaluation of efficacy of budesonide inhalation suspension for infants with severe intermittent asthma - A multicenter, open, randomized, parallel-group studybronchial asthma
JPRN-UMIN000001557Mie National Hospital80
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSISHigh risk of bronchopulmonary dysplasia in very preterm neonatesMedDRA version: 12.1Level: LLTClassification code 10006475Term: Bronchopulmonary dysplasia
EUCTR2009-012203-26-EEniversitätsklinikum Tübingen863
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSIS
EUCTR2009-012203-26-DEniversity Children's Hospital, Department of Neonatology850
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary DysplasiaSurvival of extremely Low Birth Weight (ELBW) infants has improved in recent decades but Bronchopulmonary Dysplasia (BPD) remains a major health care problem. BPD is a chronic lung disease that occurs in premature infants requiring mechanical ventilation and oxygen therapy, but also develops in preterm neonates who require little or no ventilatory or oxygen supportMedDRA version: 14.1Level: PTClassification code 10006475Term: Bronchopulmonary dysplasiaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2009-012203-26-BEniversity Children’s Hospital, Department of Neonatology850
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSIS
EUCTR2009-012203-26-NLniversity Children's Hospital, Department of Neonatology850